特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
369010

CD123:免疫療法の系列的標的

CD123: A Paradigmatic Target for Immunotherapeutic Treatment Modalities

出版日: | 発行: La Merie Publishing | ページ情報: 英文 83 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
CD123:免疫療法の系列的標的
出版日: 2016年08月31日
発行: La Merie Publishing
ページ情報: 英文 83 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

CD123 (別名:インターロイキン-3 受容体) は、造血細胞の増殖と分化に関与する細胞表面タンパク質です。

当レポートでは、CD123標的治療について調査分析し、標的の背景と科学的論拠、前臨床概念実証、臨床経験、競合情勢、主要企業プロファイルなど、体系的な情報を提供しています。

目次

  • 標的の背景と科学的論拠
  • 抗CD123免疫療法の前臨床概念実証
  • CD123標的治療による臨床経験
  • 抗CD123免疫療法の標的と治療法の安全性の懸念
  • 競合情勢
  • 抗CD123免疫療法のプロファイル
  • 企業プロファイル
  • 参考資料
  • 付録
目次
Product Code: LMBR0013

This report describes and evaluates the competitive landscape of CD123-targeted immunotherapeutics based on different treatment modalities. CD123, or the interleukin-3 receptor alpha subunit (IL-3Rα) is differentially and significantly overexpressed in a large proportion (up to 93 %) of patients with acute myeloid leukemia (AML) and has been identified as a marker of quiescent leukemic stem cells with very low or negligible expression in normal CD34+ progenitor cells. However, CD123 is normally expressed at low levels on some endothelial cells, monocytes, plasmocytoid dendritic cells (pDC), basophils, and myeloid progenitors. This expression profile makes CD123 an attractive surface target for novel antileukemic therapies.

Clinical experience showed that the simple blockade of interleukin-3 signalling by a naked antibody was an insufficient therapeutic strategy which opened the way for generation and devleopment of empowered anti-CD123 immunotherapeutics using emerging novel treatment modalities including:

  • Fc-engineered antibodies;
  • Immunotoxins;
  • Antibody-drug conjugates;
  • T-cell redirecting bispecific antibodies;
  • Chimeric Antigen Receptor (CAR) engineered T-cells.

This report describes the profiles of 16 different anti-CD123 immunotherapeutics based on different treatment modalities. The FDA recently acknowledged the anti-CD123 treatment approach by granting Breakthrough Therapy designation to the immunotoxin SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). SL-401 is the most advanced of 15 different anti-CD123 immunotherapeutis, seven of them are in earlier clinical develoment and further four are being prepared for clinical evaluation.

This report describes and analyzes the

  • Target Background & Scientific Rationale
  • Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
  • Clinical Experience with CD123-Targeted Treatment Modalities
  • Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
  • Competitive Landscape
  • Profiles of Anti-CD123 Immunotherapeutics
  • Company Profiles

Table of Contents

  • Target Background & Scientific Rationale
  • Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
  • Clinical Experience with CD123-Targeted Treatment Modalities
  • Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
  • Competitive Landscape
  • Profiles of Anti-CD123 Immunotherapeutics:
    • Immunotoxins
    • Naked Antibody
    • Fc-Engineered Antibodies
    • Antibody-Drug Conjugates
    • T-Cell Redirecting Bispecific Antibodies
    • Anti-CD123 CAR T-Cells
  • Company Profiles
  • References
  • ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.